Belite Bio (BLTE) vs Veradermics (MANE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Belite Bio is the larger company by market cap ($6.22 billion vs $5.47 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLTE | MANE |
|---|---|---|
| Share price | $154.49 | $130.90 |
| Market cap | $6.22B | $5.47B |
| 1-day change | +1.29% | +3.37% |
| YTD return | -3.42% | — |
| 1-year return | +96.80% | — |
| Forward P/E | 68.36 | — |
| EPS (TTM) | $-2.74 | $-4.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-77.61M | $-70.00M |
| 52-week high | $200.00 | $136.72 |
| 52-week low | $77.64 | $32.00 |
| Distance from 52-week high | -22.75% | -4.26% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +48.16% | +24.90% |
| Average volume | 179.38K | 779.41K |
| Shares outstanding | 40.27M | 41.78M |
| Employees | 41 | 37 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Belite Bio
BLTE stock →Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 41 employees
About Veradermics
MANE stock →Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children.
Health Care · Biotechnology: Pharmaceutical Preparations · 37 employees
BLTE vs MANE FAQ
Which is bigger, Belite Bio or Veradermics?
Belite Bio (BLTE) is larger, with a market capitalization of $6.22B compared with $5.47B for Veradermics (MANE).
Are Belite Bio and Veradermics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.